U.S. FDA approves AstraZeneca's lung cancer drugs

Send a link to a friend  Share

[November 12, 2022]  (Reuters) - Drugmaker AstraZeneca said on Friday its lung cancer drugs Imfinzi and Imjudo have been approved by the U.S. Food and Drug Administration (FDA) when used along with chemotherapy for treatment of adults with stage IV non-small cell lung cancer.

[to top of second column]

AstraZeneca's cancer medicine Imfinzi is seen in this undated handout image provided to Reuters, June 30, 2022. AstraZeneca/Handout via REUTERS

(Reporting by Amna Karimi in Bengaluru; Editing by Sherry Jacob-Phillips)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.

Back to top